Introduction
============

Colorectal cancer (CRC) is one of the most common cancers worldwide in terms of both incidence and mortality [@B1]. The diagnosis and treatment of CRC have been improved, although, despite extensive efforts, the efficacy of surgery and chemotherapy remains unsatisfactory. Most diagnosed CRC patients present with middle or late-stage cancer. Therefore, new diagnostic and treatment strategies are urgently needed. CRC development and progression consists of mutational events in oncogenes and tumor suppressor genes [@B2]. Thus, investigating genes associated with CRC development is crucial.

Grainyhead-like 2 (GRHL2) (also known as BOM or TFCP2L3), encoding a 325 amino acid protein, belongs to GRHL transcription factor family [@B3], which comprises GRHL1, GRHL2 and GRHL3 [@B4]. Grainyhead family genes have been shown to play an important role in wound healing, epidermal integrity and embryonic neural tube closure [@B5]-[@B7]. Particularly, GRHL2 is implicated in regulating structural and functional differentiation of epithelial tissues [@B8]-[@B10], and controlling many physiological functions of human airway epithelium [@B11], [@B12]. With regard to cancer, GRHL2 gene amplification has been noted in several tumors, including hepatocellular carcinoma [@B13], human oral squamous cell carcinoma [@B14], gastric cancer [@B15], breast cancer [@B16], [@B17]. As such, GRHL2 has been proposed as a candidate oncogene. On the other hand, evidences have been reported for suppressing activities of GRHL2 transcription factor in tumorigenesis. Previous studies have shown that there was a tumor suppressive role of GRHL2 in gastric cancer [@B18]. Additionally, GRHL2 could suppress EMT and restore sensitivity to anoikis in breast cancer [@B19]. GRHL3, another member of grainyhead subfamily, was recently demonstrated to suppress squamous cell carcinoma, due to its activation of PTEN expression [@B20], and modulation of the miR-21 target MSH2 by RNA-binding protein DND1 [@B21]. These controversial results suggested that the role of GRHL2 was possibly tumor specific and highly dependent on its targets in different cancer cells. However, the function and precise molecular mechanism of GRHL2 in CRC were unclear and required elucidation.

In our previous study, we performed lentivirus-mediated shRNA transfection to knock-down GRHL2 gene expression in CRC cells, and we found that down-regulation of GRHL2 inhibited the proliferation of CRC cells by targeting ZEB1[@B22]. However, how GRHL2 is associated with the clinical features of colorectal carcinoma is not known. In the current investigation, we examined the expression of GRHL2 in CRC tissue and its effects on cellular proliferation. Further, a retrospective cohort study with a five-year follow-up was performed to investigate the relativity between GRHL2 expression and prognosis in CRC. Our results demonstrated GRHL2 is a potent driver of CRC, as well as a prognostic marker to predict poor outcome in human CRC. In fact, GRHL2 over-expression promoted proliferation of CRC cells *in vitro* and enhanced the tumorigenic potential*in vivo*. These studies may provide new avenues of research with potential clinical implications.

Materials and methods
=====================

Patients and clinical specimens
-------------------------------

CRC tumor specimens and paired non-tumor mucosa were collected from December 2006 to July 2008. Patients with the following criteria were excluded from participation: had received adjuvant chemotherapy or radiotherapy prior to surgery; had additional cancers diagnoses. All patients were classified according to the 7^th^ edition of the TNM staging system [@B23]. Postoperative adjuvant therapies were performed, according to standard schedules and doses. Patients were followed-up annually by telephone or at outpatient clinic till July, 2013 or dead. Overall survival was defined as the time elapsed from surgery to the time of patient death. Patients\' death information was obtained from their family. All participating patients gave their written informed consent. This study was approved by the Ethical Committee of Shanghai Pudong Hospital.

Immunohistochemical staining
----------------------------

Immunohistochemistry (IHC) stains were performed using formalin-fixed, paraffin-embedded tissue sections of tissue blocks, according to the well-established protocols [@B24]. The primary antibody used was the rabbit monoclonal anti-GRHL2 antibody (HPA004820, Sigma, St. Louis, MO, USA) at 1: 300 dilutions. Negative controls were stained with IgG as primary antibody. We scored the GRHL2 IHC staining based on the proportion of cell staining and the staining intensity. The percentage of positive cells was divided into five grades (percentage scores) : \<10 % (0), 10-25 % (1), 25-50 % (2), 50-75 % (3) and\>75 % (4). The intensity of staining was divided into four grades (intensity scores): no staining (0), weak staining (1), moderate staining (2) and strong staining (3). GRHL2 staining positivity was determined by the following formula: overall score = percentage score × intensity score. The overall score ≤ 3 was defined as negative, and \> 3 was defined as positive. GRHL2 staining was scored by two independent researchers, blinded to the clinical characteristics of the patients.

Cell lines and cell culture
---------------------------

Human colorectal cancer cells HCT116, SW116, LoVo, SW480 and Caco2 were preserved in our institute. These cells were grown in RPMI-1640(Corning Cellgro^®^, Manassas, VA, USA) medium containing 10 % fetal bovine serum (FBS, Corning Cellgro^®^). HT29 and SW620 cells were obtained from the American Type Culture Collection (ATCC), grown in McCoy\'s 5A (for HT29) and Leibovitz\'s L-15 medium (for SW620) supplemented with 10% (v/v) FBS (Corning Cellgro^®^), penicillin and streptomycin (GIBCO BRL, Gaithersburg, MD, USA). All the cells were cultured at 37℃ in a humidified atmosphere of 5% CO~2~.

Generation of stable cell lines by lentiviral transduction
----------------------------------------------------------

For GRHL2 over-expression, human GRHL2 full length cDNA was amplified, introduced into the LV5 vector, and cloned into the NotI/BamHI sites of the V2251-2 plasmid (GenePharma, Shanghai, China). HT29 and SW620 cells infected with lentiviral vectors expressing GRHL2 or empty vector were performed for 12 h in the presence of 5μg/ml polybrene (Santa Cruz, Dallas, Texas, USA). Infected cells were selected for more than 2 weeks by incubation with puromycin (5μg/ml for HT29, 3μg/ml for SW620), followed by qRT-PCR and western blot analysis to verify GRHL2 expression. Stable transfectant cells were maintained in medium containing 1 µg/ml puromycin.

Quantitative real-time PCR
--------------------------

Total RNA extracts were prepared from cell cultures using Trizol (Invitrogen, Grand Island, NY, USA) according to the manufacturer\'s protocol. cDNA was amplified using a reverse transcriptional kit (Promega, Madison, WI, USA). The qRT-PCR was carried out using cDNA as a template and Universal PCR Master Mix (Applied Biosystems, Carlsbad, CA, USA) on an Applied Biosystems 7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA). Primers used for qRT-PCR analysis were as follows: GRHL2: GGAAATCTAGCCCTGGGTTTG (forward) and TCAGGGAGGAACGCACTGA (reverse). GAPDH: AAGGTGAA-GGTCGGAGTCAAC (forward) and GGGGTCATTGATGGCAACAATA (reverse). The relative amount of mRNA was normalized using GAPDH as endogenous control.

Western blot
------------

Whole cellular or tissue proteins were extracted with RIPA lysis buffer (Solarbio, Beijing, China) containing 0.2 mM phenylmethylsulfonyl fluoride (PMSF), according to standard methods. Protein concentrations were determined by the Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). Western blot was performed via established protocols [@B25]. Primary antibodies used in this study were as follows: GRHL2 (1:300, Cat. HPA004820, Sigma); cyclin A (1:500, Cat. sc-596), cyclin D1 (1:500, Cat. sc-753), p21 (1:500, Cat. sc-397), p27 (1:500, Cat. sc-528) were from Santa Cruz biotechnology. The secondary antibodies used were horseradish peroxidase (HRP)-conjugated anti-rabbit (1:1000, Cat. 7074) and anti-mouse (1:1000, Cat. 7076) from Cell Signaling Technology; Primary antibody against GAPDH (1:5000, Cat. sc-365062, Santa Cruz, USA) was used as a loading control.

Cell proliferation assay
------------------------

Cell proliferation assays were performed using a Cell Counting Kit-8 (CCK-8; cat.CK04, DOJINDO, Kumamoto, Japan) following the manufacturer\'s protocol. Parental, Vector and GRHL2+ cells were seeded in a 96-well plate (3000 cells per well) and cultured for 24, 48, 72, 96 and 120 h. Then, 10 μl of the CCK-8 solution was added to each well of the plate and incubated for another 3 hours. The absorbance at 450 nm was measured with a microplate reader.

Colony formation assay
----------------------

Parental, Vector and GRHL2+ cells (1000 cells per well) were plated at low densities in six-well plates and incubated for 14 days with the medium replaced every 3 days. Cells were washed twice with PBS, fixed and then stained with 1% crystal violet staining solution. The number of colonies containing more than 50 cells was counted under a microscope.

Flow cytometry
--------------

Vector and GRHL2+ cells were fixed in 70% ice-cold ethanol overnight at 4℃, and then incubated with 100 ug/mL RNase at 37℃ for 20 min. After staining with propidium iodide (50 ug/mL, Roche Applied Science, Basel, Switzerland), the cells were subjected to fluorescence activated cell sorting (FACS) on a FACScan (Beckman Instruments, Fullerton, CA, USA). The cell populations were quantified using the Modfit software (Becton-Dickinson).

Experimental *in vivo* animal model
-----------------------------------

Male BALB/c nu/nu nude mice (Institute of Zoology Chinese Academy of Sciences), 4-week-old, were housed at a specific pathogen-free environment in the Animal Laboratory Unit. Mice (6 mice per group) were subcutaneously implanted with Vector and GRHL2+ cells (1 × 10^6^ in 0.1 ml of sterilized PBS buffer). Tumor growth were determined by measuring the size (mm^3^, V = (Width^2^× Length) / 2) every 4 days using calipers [@B26]. The mice were euthanized after 32 days post-inoculation, and tumor were excised for analyzing. Mice received humane care and the study protocols comply with the Institution\'s guidelines and animal research laws.

Statistical Analysis
--------------------

IBM SPSS Statistical software (version 19.0) was utilized for statistical analysis. Correlations between GRHL2 expression in CRC tissues and clinicopathological parameters were analyzed using the Pearson\'s Chi-square (χ^2^) test. Overall survival (OS) and recurrence-free survival (RFS) were evaluated with the Kaplan-Meier method and differences were compared by log-rank test. Cox\'s proportional hazards modeling of factors potentially related to survival were conducted to calculate hazard ratios (HR). Differences were compared using a two-tailed Student\'s t test. All *P*-values were determined from 2-tailed tests and differences with a *P*-value\<0.05 were considered to be statistically significant.

Results
=======

GRHL2 expression was increased in CRC tissues comparing to the paired non-tumor tissues and varied in CRC cell lines
--------------------------------------------------------------------------------------------------------------------

To gain insights into the role of GRHL2 in colorectal tumorigenesis, we examined its expression in primary CRC and paired normal mucosal tissues by IHC staining. Representative staining results were shown in Figure [1](#F1){ref-type="fig"}. IHC staining indicated that GRHL2 was predominantly presented in the nucleus in CRC cells and normal cells in the paired normal colorectal mucosa. Among 171 cases, 106(62.0%) were positive for GRHL2 expression (Fig. [1](#F1){ref-type="fig"}D-F), while 65 (38.0%) were negative for GRHL2 expression (Fig. [1](#F1){ref-type="fig"}C), only 74/171 (43.2%) matched normal mucosa were detected with positive GRHL2 expression (Fig. [1](#F1){ref-type="fig"}B). Collectively, GRHL2 levels were significantly higher in CRC tissues than non-tumor tissues (*P*=0.001, Table [1](#T1){ref-type="table"}). This indicated that GRHL2 might facilitate tumorigenesis in colon.

To investigate whether there was heterogeneity in the expression of GRHL2 in different CRC cell lines, qRT-PCR (Fig. [1](#F1){ref-type="fig"}G) and western blot (Fig. [1](#F1){ref-type="fig"}H) were performed to assess GRHL2 gene transcripts and proteins levels. GRHL2 expression was varied in seven different CRC cell lines. Five of which showed a high expression, including HCT116, LoVo, HT29, SW480 and Caco2 cells. Low level expression of GRHL2 was found in SW620 and SW1116 cells.

GRHL2 expression correlated with different clinicopathologic parameters
-----------------------------------------------------------------------

Considering the level of GRHL2 in CRC tissues was significantly higher than that in non-tumor tissues, the correlations between GRHL2 expression and clinicopathologic parameters in CRC were analyzed by Pearson\'s Chi-square. We subdivided the CRC cases in two groups according to GRHL2 levels (negative and positive). Correlation analysis demonstrated that the positive expression of GRHL2 was correlated with the large tumor size, later clinical stage in CRCs (*p*\<0.05), but was not significantly correlated to gender, tumor location, cell differentiation (Table [2](#T2){ref-type="table"}). GRHL2 level was higher in advanced tumor stages III+IV than tumor stages I+II (69.2% vs. 53.8%, *p* =0.037). Larger tumor size was found with higher GRHL2 expression (67.9% vs. 51.6%, *p* =0.035). Our data revealed that GRHL2 was highly expressed in the more aggressive tumors and had a correlation with the well-established prognostic evaluation factors. Hence, GRHL2 could be used as a potential unfavorable prognostic biomarker for CRC.

GRHL2 expression was associated with poor clinical outcomes
-----------------------------------------------------------

We next investigated the correlation of GRHL2 expression with patient survival. At the end of the follow-up period (60 months), 93 of the 171 patients were alive, 78 patients were dead. Patients were then divided into two groups: GRHL2 (+) and GRHL2 (-). A Kaplan-Meier survival analysis revealed that GRHL2 up-regulation was associated with a lower OS rate (*p*=0.003, Fig. [2](#F2){ref-type="fig"}A) and RFS (*p*=0.006, Fig. [2](#F2){ref-type="fig"}B). Further multivariate Cox regression analysis determined GRHL2 positive-expression was an independent prognostic factor for the poor OS (HR=0.545, *p*=0.018, Table [3](#T3){ref-type="table"}) and lower RFS (HR=0.601, *p*=0.036, Table [3](#T3){ref-type="table"}) in CRC patients. Thus, GRHL2 could be a potential biomarker indicating poor outcome in CRC patient.

GRHL2 promoted cell proliferation of CRC cell lines *in vitro*
--------------------------------------------------------------

Given that GRHL2 was positively correlated with tumor stage in CRC clinical specimens, we sought to further investigate its influence on cell proliferation *in vitro*. We utilized human CRC cells HT29 and SW620 to establish the model stably over-expressing exogenous human GRHL2 by lentivirus-mediated experiments. Both qRT-PCR (Fig. [3](#F3){ref-type="fig"}A) and western blot analysis (Fig. [3](#F3){ref-type="fig"}B) demonstrated that HT29/GRHL2+ cells (*p*\<0.01) and SW620/GRHL2+ (*p*\<0.001) had a significant increase of GRHL2 expression relative to their empty vector transfected control and parental control cells.

To assess the effects of GRHL2 on cell growth, CCK-8 assays were performed. Cells transfected with GRHL2 demonstrated a significant increase in proliferation rate relative to vector control or parental cells. A significant higher proliferation rate was observed in HT29/GRHL2+ and SW620/GRHL2+ cells (Fig. [3](#F3){ref-type="fig"}C). GRHL2 over-expression resulted in a significant increase in colony formation in HT29 and SW620 cells (Fig. [3](#F3){ref-type="fig"}D). We then examined cell-cycle distribution in GRHL2-over-expressed cells. The percentage of cells in S phase and G~2~/M phase was increased in HT29/GRHL2+ and SW620/GRHL2+ cells, while reduced in G~1~ phase comparing to vector control cells (Fig. [3](#F3){ref-type="fig"}E). This indicated that the growth-promoted effect of GRHL2 may partly due to the alteration of cell cycle distribution. Furthermore, we assessed the proliferation markers (such as cyclin A, cyclin D1, p21, p27) expression by western blot analysis. Consistently, over-expressing GRHL2 resulted in a significant increase of the expression of cyclin A and cyclin D1, while attenuating p21 and p27 levels (Fig. [4](#F4){ref-type="fig"}A&B). Collectively, GRHL2 expression promoted cellular proliferation and tumor growth *in vitro*.

GRHL2 increased the tumorigenic potential of CRC cell line *in vivo*
--------------------------------------------------------------------

Since GRHL2 plays an oncogenic role *in vitro*, it was very important to assess its effect *in vivo*. Studies were performed utilizing the xenograft model by injecting Vector and GRHL2 cells subcutaneously into the nude mice, respectively. As demonstrated in Figure [5](#F5){ref-type="fig"}, over-expression of GRHL2 in HT29 and SW620 cells promoted tumor growth (Fig. [5](#F5){ref-type="fig"}A), compared to the Vector cells. Notably, the average volume and weight of tumors excised after 32 days post-inoculation in GRHL2+ groups were markedly larger and heavier than those in Vector groups (Fig. [4](#F4){ref-type="fig"}B-D). Furthermore, we also assessed the proliferation markers expression in mice tumor masses by western blot analysis. Similar to the observation *in vitro*, GRHL2+ groups had an increase in the expression of cyclin A and cyclin D1, while a decrease in the levels of p21 and p27 (Fig. [5](#F5){ref-type="fig"}E). Altogether, these data clearly demonstrated that GRHL2 expression promoted tumor growth *in vivo*.

Discussion
==========

The precise molecular mechanisms underlying CRC tumorigenesis is crucial, as it can help us to develop novel therapeutic strategies for CRC patients [@B27]. In recent studies, GRHL2 aroused great interest and was selected as a candidate gene since it has been reported to be involved in several malignant tumors [@B13]-[@B17]. GRHL2 is a transcriptional regulator of proliferation and differentiation in epithelial cells, both during development and tumorigenesis. Although GRHL2 was demonstrated to act as an oncogene in several tumors, its role in CRC remains unclear. Herein, we examined GRHL2 expression in CRC and paired normal colorectal epithelium, and found that GRHL2 was over-expressed in CRC. We gave the first evidence that GRHL2 plays a pivotal role in CRC tumorigenesis. The characteristics observed in patients with CRC were recapitulated in cells and mouse xenograft models. Over-expressing GRHL2 in HT29 and SW620 cells induced an increase in cellular proliferation, and promoting tumor growth *in vivo*. To date, however, evidence has been reported for tumor-suppressing activities of GRHL2 transcription factor in tumorigenesis [@B18]. These conflicting data suggests that GRHL2 may have dual functions depending on the cell background and cancer type [@B28].

The abilities to predict outcome and to identify key players in biological mechanisms that lead to poor outcome are two important objectives in cancer research. In this study, we included 171 CRC specimens with various TNM stages (I-IV) to investigate the clinical potential of GRHL2 alone as an independent prognostic factor. Our study demonstrated that GRHL2 expression positively correlated with large tumor size, later TNM stage. Intriguingly, Kaplan-Meier analysis showed that CRC patients with GRHL2-positive tumors had significantly worse prognosis in both OS and RFS. In agreement with our study, using a large public microarray database, Xiang [@B16] found that higher expression levels of GRHL2 was significantly correlated with a shorter relapse-free survival interval. In hepatocellular carcinoma, GRHL2 was demonstrated to be an independent predictive marker for HCC recurrence [@B13]. Thus, our study further confirmed that GRHL2 could be used as an unfavorable prognostic biomarker for CRC patients.

The deregulation of cell proliferation is a prerequisite for carcinogenesis and cancer progression [@B29]. The achievement of the proliferation follows from the activation/inactivation of signaling pathways regulating this process [@B30]. In the context of cancer, this occurs owing to both the activation of oncogenes and the inactivation of tumor suppressors regulating proliferation [@B31]. The association between proliferation and poor prognosis has been established [@B32]. Previous studies suggest that GRHL2 is involved in cell proliferation. GRHL2 knocking-down markedly repressed hepatoma cells growth [@B13]. Loss of GRHL2 induced a striking reduction in cell proliferation in breast cancer [@B28]. Importantly, GRHL2 appears to be a critical factor for hTERT expression and telomerase activity, GRHL2 over-expression prevented the senescence-associated loss of telomerase activity and enhanced cellular proliferation in oral carcinoma [@B14]. Also, GRHL2 was shown to significantly promote tumor growth and metastasis in breast cancer [@B16]. In the current study, we demonstrated that over-expressing GRHL2 promotes cell cycle progression, as documented by the significant enrichment of the cell population in the S and G2/M phase. Consistently, modulation of GRHL2 levels resulted in significant changes in the expression of the proliferation marker proteins *in vitro* and *in vivo*.

In conclusion, we identified GRHL2, as an oncogene, was frequently over-expressed in CRC tissues and cell lines. In fact, high GRHL2 level correlates with poorer prognosis in CRC. GRHL2 over-expression was demonstrated to promote CRC progression both *in vitro* and *in vivo*. Furthermore, GRHL2 could regulate cell cycle and modulate cell cycle proteins. In fact, our current results indicate that GRHL2 can be used as a novel predictive biomarker and potential therapeutic target for CRC.

We thank Yan Shen for help of performing the mouse xenografts experiment. This work was supported by the Pudong Hospital Funds for Distinguished Young Scientists (201407Y).

![**GRHL2 expression was increased in colorectal cancer (CRC) tissues and varied in CRC cell lines.**(A) GRHL2-negative normal mucosa epithelium adjacent to carcinoma. (B) Nuclear staining of GRHL2 in normal epithelium adjacent to cancer. (C) GRHL2-negative cancer tissue. (D) Moderate positive nuclear stain for GRHL2 in cancer tissue. (E-F) Strong nuclear staining for GRHL2 in CRC tissue. The scale bar indicates 100 um. Original Magnification: × 200 (A-D, F), × 100 (E). (G) The expression of GRHL2 gene transcripts in a panel of human CRC cell lines were detected by qRT-PCR. The relative amount of mRNA was normalized using GAPDH as endogenous control. (H) GRHL2 protein levels were detected by western blot, with GAPDH as control.](jcav06p0342g001){#F1}

![**GRHL2 expression was associated with poor clinical outcomes.**(A) Kaplan-Meier survival analysis of OS of CRCs according to the expression level of GRHL2 protein. GRHL2 up-regulation was associated with a lower OS, compared with GRHL2-negative CRC patients (*p*=0.003, log-rank test). (B) Kaplan-Meier survival analysis of RFS of CRC patients according to the expression level of GRHL2. Positive expression were associated with a shorter RFS (*p*=0.006, log-rank test).](jcav06p0342g002){#F2}

![**Over-expression of GRHL2 promoted proliferation of CRC cell lines *in vitro*.**(A) A qRT-PCR analysis of GRHL2 gene expression revealed a striking up-regulation of exogenous GRHL2 expression in HT29 (HT29/GRHL2+) and SW620 (SW620/GRHL2+) cells compared to Parental and Vector cells. (B) In HT29/GRHL+ and SW620/GRHL2 cells, there were a marked increase in the expression of GRHL2, verified by western blot. Immunoblotting results are typical blots from 3 experiments. Densitometric analysis was expressed relative to the loading control, GAPDH. (C) Effect of GRHL2 on cellular proliferation was measured by CCK-8 assay. HT29/GRHL+ and SW620/GRHL2 cells showed higher proliferation than control cells. (D) GRHL2 over-expression resulted in a significant increase in colony formation in GRHL2+ cell. (E) Representative charts for cell-cycle distribution in Vector and GRHL2 cells. Results are mean ± SD (3-5 experiments). \*Relative to Vector control; \#relative to Parental control. \* *p*\<0.05, \*\* *p*\<0.01, \*\*\* *p*\<0.001, \# *p*\<0.05, \# *p*\<0.01, \#\#\# *p*\<0.001.](jcav06p0342g003){#F3}

![**Over-expression of GRHL2 modulated the expression of proliferation marker proteins.**The proliferation marker proteins were assessed by western blot analysis. Over-expression GRHL2 in HT29 (A) and SW620 (B) cells significant increased the expression of cyclin A and cyclin D1, while decreasing the levels of p21 and p27. Immunoblotting results are typical from 3 experiments and the densitometry is mean ± SD (3-5 experiments) \*Relative to Vector control \* *p*\<0.05, \*\* *p*\<0.01.](jcav06p0342g004){#F4}

![**Over-expression of GRHL2 increased the tumorigenic potential of CRC cell lines *in vivo*.**(A) Tumor growth curves demonstrated over-expression of GRHL2 promoted tumor growth. Tumor sizes were examined every 4 days after implantation of Vector cells and GRHL2+ cells. (B) The tumor masses originated from GRHL+ cells were larger than tumors from Vector cells. (C) As compared with Vector controls, the average tumor volume of the GRHL2+ group was markedly larger. (D) The average weight of primary tumors originated from GRHL2 groups was heavier than that from Vector groups. (E) GRHL2over-expression significantly increased the expression of the proliferation markers cyclin A and cyclin D1, while decreasing the levels of p21 and p27. Each data point represents the mean ± SD (3-5 experiments). Densitometric analysis is expressed relative to the loading control, GAPDH. \*Relative to Vector control \* *p*\<0.05, \*\* *p*\<0.01, \*\*\* *p*\<0.001.](jcav06p0342g005){#F5}

###### 

Expression of GRHL2 in colorectal cancer tissues and matched non-tumor mucosa

                         Total   GRHL2(-)   GRHL2(+)    *P*value
  ---------------------- ------- ---------- ----------- ----------
  **tumor specimens**    171     65 (38%)   106 (62%)   0.001\*
  **non-tumor mucosa**   171     97 (57%)   74 (43%)    

\*Statistically significant

###### 

Correlation of GRHL2 with different clinicopathologic parameters

  Parameters                                        GRHL2 expression               
  ------------------ ------------------ ----------- ------------------ ----------- ---------
  **Age**            \<60               77          30(39.0%)          47(61.0%)   0.974
  ≧60                94                 35(37.2%)   59(62.8%)                      
  **Gender**         Male               97          40(41.2%)          57(58.8%)   0.323
  Female             74                 25(33.8%)   49(66.2%)                      
  **Histology**      Tubular            136         57(41.9%)          79(58.1%)   0.060
  Mucinous           28                 7 (25.0%)   21(75.0%)                      
  Papillary          7                  1 (14.3%)   6 (85.7%)                      
  **Site**           Rectum & sigmoid   112         38(33.9%)          74(66.1%)   0.053
  Right colon        40                 21(52.5%)   19(47.5%)                      
  Left colon         19                 6(31.6%)    13(68.4%)                      
  **Size status**    \<3cm              62          30(48.4%)          32(51.6%)   0.035\*
  ≧3cm               109                35(32.1%)   74(67.9%)                      
  **Stage status**   I+ II              80          37(46.3%)          43(53.7%)   0.037\*
  III+IV             91                 28(30.8%)   63(69.2%)                      

\*Statistically significant

###### 

Univariate and multivariate analysis of clinicopathlogical parameters with overall survival (OS ) and recurrence-free survival(RFS) by Cox proportional hazards regression.

  ------------------------------------------------------------------------------------------
  Factors              Univeriate   Multivariate                                   
  -------------------- ------------ -------------- --------- ------- ------------- ---------
  **OS**                                                                           

  **Age**              0.993        0.972-1.015    0.525                           

  **Gender**           0.903        0.575-1.418    0.658                           

  **Histology**        1.020        0.760-1.370    0.894                           

  **Site**\            1.151\       0.878-1.508\   0.309\                          
  **Size**             1.036        0.654-1.640    0.880                           

  **Clinical stage**   1.792        1.415-2.270    0.000\*   1.728   1.365-2.187   0.000\*

  **GRHL2**            0.481        0.291-0.793    0.004\*   0.545   0.329-0.902   0.018\*

  **RFS**                                                                          

  **Age**              1.000        0.980-1.021    0.995                           

  **Gender**           0.934        0.608-1.433    0.753                           

  **Histology**        0.927        0.706-1.217    0.585                           

  **Site**\            1.185\       0.912-1.539\   0.205\                          
  **Size**             1.031        0.663-1.601    0.894                           

  **Clinical stage**   1.936        1.530-2.450    0.000\*   1.879   1.484-2.379   0.000\*

  **GRHL2**            0.522        0.326-0.837    0.007\*   0.601   0.374-0.967   0.036\*
  ------------------------------------------------------------------------------------------

\*Statistically significant
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